Category: LARGE CAP PSYCH

Compass Pathways (CMPS) Reports 2Q and Business Highlights.

"Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in...

Atai Life Sciences (ATAI) Presentation Deck.

PRESENTATION DECK - JULY 2021 LIVE QUOTE Decks contain forward-looking statements. All...

Atai Life Sciences (ATAI)

LIVE NEWS LIVE QUOTE PRESENTATION...

Compass Pathways (CMPS)

LIVE NEWS PRESENTATION DECK - JUNE 2021

MindMed (MNMD)

PRESENTATION DECK - JUNE 2021 Decks contain forward-looking statements. All statements other than statements of historical...
Most Popular

Psychedelic Drugs ‘Far Exceed’ Cannabis Investment Potential (CNBC)

Shark Tank’s Kevin O’Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr....

Psychedelic Therapeutics Sector Outlook Released (Valhalla Ventures)

Valhalla Ventures backs visionary founders at the forefront of social and technological movements that younger generations care about most.

2021 Psychedelic Investor Guide Released.

Institutional Analyst Inc. announced the release of the 2021 Psychedelic Investor Guide on Monday, October 18th. The Psychedelic Investor Guide is the...